Valneva initiates Phase 1/2 clinical study of inactivated, adjuvanted COVID-19 vaccine candidate
- Details
- Category: Business

VLA2001 leverages the manufacturing platform of Valneva's licensed Japanese encephalitis vaccine, IXIARO® and is the first publicly announced inactivated vaccine against COVID-19 to commence clinical development in Europe.
Moderna announces first participants dosed in Phase 2/3 study of COVID-19 vaccine candidate in adolescents
- Details
- Category: Business

Moderna announces primary efficacy analysis in Phase 3 COVE study for its COVID-19 vaccine candidate and filing today with U.S. FDA for Emergency Use Authorization
- Details
- Category: Business

Moderna's COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study
- Details
- Category: Business

Swissmedic begins rolling review of Moderna's mRNA vaccine against COVID-19 (mRNA-1273)
- Details
- Category: Business

The Sputnik V COVID-19 vaccine efficacy amounted to 92% in Phase III clinical trials
- Details
- Category: Business

Novavax COVID-19 vaccine granted Fast Track Designation by U.S. FDA
- Details
- Category: Business

More Pharma News ...
- Novavax announces facility expansion to support global vaccine development
- RDIF and União Química file documents for registration of Sputnik V vaccine with regulator in Brazil
- Russian application of Sputnik V vaccine for WHO vaccine prequalification among the first applications submitted
- Novavax provides Phase 3 COVID-19 vaccine clinical development update
- Moderna announces supply agreement with the Ministry of Public Health to supply Qatar with mRNA vaccine against COVID-19 (mRNA-1273)
- CureVac reports positive preclinical data for its COVID-19 vaccine candidate, CVnCoV
- Moderna completes enrollment of Phase 3 COVE study of mRNA vaccine against COVID-19 (mRNA-1273)